Breaking a paradigm: IL-6/STAT3 signaling suppresses metastatic prostate cancer upon ARF expression. (3rd March 2016)

• Record Type: Journal Article
• Authors: Culig, Zoran; Pencik, Jan; Merkel, Olaf; Kenner, Lukas
• Is Part Of: Molecular & cellular oncology. Volume 3:Number 2(2016)
• Publication Date: 2016-03-03
• Subjects: ARF -- CDK4/CDK6 inhibitors -- IL-6 -- Metastasis -- Prostate cancer -- Senescence -- STAT3; Tumors -- Periodicals; Neoplasms; Periodicals; 616.99
• DOI: 10.1080/23723556.2015.1090048
• Languages: English
• ISSNs: 2372-3556

Abstract

ABSTRACT: Interleukin 6 (IL-6)/signal transducer and activator of transcription 3 (STAT3) signaling is considered to have important oncogenic functions in prostate cancer (PCa). However, a recent study highlighted the central role of IL-6/STAT3 signaling in regulation of the ARF–MDM2–p53 senescence axis. This reversal of the postulated oncogenic properties of IL-6/STAT3 signaling in PCa has important therapeutic implications.